Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Avadel wins FDA approval for narcolepsy drug Lumryz
Avadel wins FDA approval for narcolepsy drug Lumryz in children
The expanded approval intensifies the rivalry with Jazz Pharmaceuticals, which has previously attempted to block Lumryz’s path to market.
Avadel Obtains FDA Nod for Label Expansion of Narcolepsy Drug Lumryz
Avadel Pharmaceuticals plc AVDL announced that the FDA has approved its supplemental new drug application (sNDA) seeking label expansion of Lumryz. The drug is now approved in the United States for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients aged seven years and older with narcolepsy.
FDA OKs Once-Nightly Lumryz for Children with Narcolepsy
Lumryz is the only FDA-approved once-at-bedtime oxybate treatment for cataplexy or excessive daytime sleepiness in children as young as 7 years with narcolepsy.
Avadel's narcolepsy drug Lumryz gets USFDA approval for pediatric use
Avadel's drug contains a central nervous system depressant drug called sodium oxybate, which helps increase the amount of time someone spends in deep sleep.
Avadel Gets Expanded FDA OK of Lumryz for Use in Children
Avadel Pharmaceuticals has won expanded Food and Drug Administration approval of its narcolepsy drug Lumryz for use in children. Avadel on Thursday said the FDA nod covers Lumryz for the treatment of cataplexy, or excessive daytime sleepiness, in children ages seven and older with narcolepsy, a chronic sleep disorder.
Avadel Pharma's SNDA For Lumryz Gets FDA Approval
Biopharmaceutical company Avadel Pharmaceuticals plc (AVDL), Thursday announced that the U.S. Food and Drug Administration (FDA) has
US FDA expands use of Avadel's sleep disorder drug to ages 7 and up
The U.S. Food and Drug Administration has approved Avadel Pharmaceuticals' sleep disorder drug for children aged 7 years and older, broadening its use and heating up competition for popular treatments from Jazz Pharmaceuticals.
clinicaladvisor.com
2d
Lumryz Approval Expanded to Include Pediatric Narcolepsy
Lumryz is an extended-release formulation of sodium oxybate, a central nervous system (CNS) depressant. Its therapeutic effects are believed to be mediated through GABA B actions at noradrenergic and ...
4d
Jazz Pharmaceuticals: Unexpected Wins Improve The Long-Term Outlook
Shares of Jazz Pharmaceuticals are trading only slightly higher in the last few weeks despite two unexpected wins. Explore ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Liberty win first WNBA title
WWII code talker dies
Helicopter hits radio tower
The Vessel to reopen
Gold hits fresh high
Southern Miss fires coach
Oscar makes landfall
Albany State shooting
American activist Wair dies
Hezbollah assets targeted
Ceasefire talks in Beirut
Wins third PGA Tour title
New Mexico flash flooding
Opens up on Russian camp
Advance to World Series
Boat rider arrested in FL
Launches OneWeb mission
Oakland fire burns homes
Baldwin returns to 'SNL'
Reaches tentative union deal
Urges support for Ukraine
Rock & Roll HOF '24 class
CVS workers strike
Trump's Pennsylvania rally
US deficit reaches $1.8T
Ferry dock collapses in GA
Orionids meteor shower
US probing documents leak
Postpones US tour
Feedback